{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Remote-Central-Monitoring-Procedures”
},
“headline”: “SOP for Remote and Central Monitoring Procedures in Clinical Trials”,
“description”: “This SOP outlines standardized processes for conducting remote and central monitoring in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP guidance while supporting risk-based monitoring models.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Remote/Central Monitoring Procedures

Purpose

The purpose of this SOP is to establish standardized procedures for conducting remote and central monitoring of clinical trials. These approaches complement or replace traditional onsite monitoring in specific scenarios, allowing continuous oversight of trial conduct, subject safety, and data integrity while supporting risk-based monitoring (RBM) frameworks.

Scope

This SOP applies to sponsors, CROs, CRAs, data managers, and QA officers engaged in clinical trial oversight. It covers remote monitoring (site-level review conducted offsite) and central monitoring (system-level oversight using aggregated data). It applies to EDC, CDMS, eTMF, safety databases, and laboratory systems used for clinical data management.

Responsibilities

• Sponsor: Approves remote/central monitoring strategies and ensures compliance with ICH GCP.
• Clinical Operations Manager: Defines monitoring methods, visit schedules, and escalation triggers.
• CRA/Monitor: Conducts remote monitoring visits, documents findings, and communicates with sites.
• Central Monitoring Team: Performs centralized data review, trend analysis, and signal detection.
• PI: Provides secure remote access to subject records and responds to monitoring queries.
• QA Officer: Verifies monitoring documentation and inspects RBM implementation.

Accountability

The sponsor is accountable for ensuring remote and central monitoring activities are conducted per protocol, GCP, and regulatory requirements. Clinical Operations is accountable for execution, while QA ensures oversight and compliance.

Procedure

1. Planning Remote/Central Monitoring
Conduct risk assessment to determine feasibility of remote or central monitoring.
Define critical data elements and processes requiring remote oversight.
Document monitoring strategy in Monitoring Plan (Annexure-1).

2. Remote Monitoring Preparation
Notify site at least 2 weeks prior to scheduled remote monitoring session.
Ensure secure remote access is granted through validated portals.
Prepare Remote Monitoring Checklist (Annexure-2).

3. Conduct of Remote Monitoring
CRA reviews eCRFs, informed consent scans, drug accountability records, and training logs remotely.
Conduct video/teleconferences with PI and staff to address open queries.
Document discrepancies in Remote Monitoring Report (Annexure-3).

4. Central Monitoring Activities
Aggregate site data into centralized dashboards.
Analyze KRIs (e.g., SAE reporting delays, outlier data trends, high protocol deviations).
Generate Central Monitoring Review Report (Annexure-4).

5. Documentation and Reporting
File remote and central monitoring reports in TMF.
Communicate findings to site and sponsor within 7 working days.
Initiate CAPA for significant findings (Annexure-5).

6. Frequency
Remote monitoring conducted every 4–6 weeks or as per risk profile.
Central monitoring performed continuously or monthly depending on trial design.

7. Escalation
Critical findings such as fraudulent data, subject safety concerns, or repeated non-compliance must be escalated within 24 hours.
Record in Escalation Log (Annexure-6).

8. Archiving
Archive monitoring reports, dashboards, checklists, and CAPA documentation in TMF/ISF.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• RBM: Risk-Based Monitoring
• KRI: Key Risk Indicator
• SDV: Source Data Verification

Documents

1. Monitoring Plan (Annexure-1)
2. Remote Monitoring Checklist (Annexure-2)
3. Remote Monitoring Report (Annexure-3)
4. Central Monitoring Review Report (Annexure-4)
5. CAPA Log (Annexure-5)
6. Escalation Log (Annexure-6)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Reflection Paper on RBM
• CDSCO – Clinical Monitoring Guidelines
• WHO – Remote Monitoring Practices

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Plan

Annexure-2: Remote Monitoring Checklist

Annexure-3: Remote Monitoring Report

Annexure-4: Central Monitoring Review Report

Annexure-5: CAPA Log

Annexure-6: Escalation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Onsite-Monitoring-Visits-and-Source-Data-Verification”
},
“headline”: “SOP for Onsite Monitoring Visits and Source Data Verification”,
“description”: “This SOP describes procedures for conducting onsite monitoring visits and performing source data verification (SDV) in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP standards.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Onsite Monitoring Visits and Source Data Verification

Purpose

The purpose of this SOP is to define the standardized procedures for conducting onsite monitoring visits and performing Source Data Verification (SDV) in clinical trials. Onsite monitoring ensures participant safety, data integrity, compliance with the protocol, and adherence to ICH GCP, FDA, EMA, CDSCO, and WHO requirements.

Scope

This SOP applies to Clinical Research Associates (CRAs), sponsors, CROs, investigators, and QA personnel involved in trial oversight. It covers preparation, conduct, and follow-up of onsite monitoring visits, as well as verification of source data against Case Report Forms (CRFs) and electronic data capture (EDC) systems.

Responsibilities

• CRA/Monitor: Conducts onsite visits, performs SDV, and documents findings in monitoring reports.
• PI: Ensures site staff facilitate monitoring activities and provides access to source documents.
• Study Coordinator: Prepares essential documents and subject records for CRA review.
• Sponsor/CRO: Defines monitoring visit frequency and ensures timely follow-up on findings.
• QA Officer: Reviews monitoring documentation and audits selected visits.

Accountability

The sponsor is accountable for ensuring monitoring visits are planned and executed. The CRA is accountable for conducting SDV and documenting deviations or discrepancies. The PI is accountable for site compliance and implementation of corrective actions.

Procedure

1. Pre-Visit Preparation
CRA reviews protocol, Investigator Site File (ISF), prior monitoring reports, and site status.
Notify PI and study coordinator at least 2 weeks prior to visit.
Prepare Monitoring Visit Checklist (Annexure-1).

2. Conduct of Onsite Visit
Meet with PI and staff to review site progress and issues.
Verify informed consent process and ensure original signed forms are filed.
Review protocol compliance including visit schedules, dosing, and procedures.
Conduct Source Data Verification (SDV): compare CRF entries with source documents (lab reports, hospital records, AE/SAE notes).
Check drug accountability and investigational product (IP) storage conditions.
Review essential documents including delegation logs, training records, and regulatory binders.

3. Documentation During Visit
Record findings in Monitoring Visit Report (Annexure-2).
Document major deviations, missing data, or inconsistencies.
Discuss preliminary findings with PI at end of visit.

4. Post-Visit Activities
Submit monitoring report within 7 working days.
File report in TMF and ISF.
Ensure CAPA plans are initiated for deviations (Annexure-3).

5. Frequency of Visits
Conduct first monitoring visit within 4 weeks of first subject enrollment.
Subsequent visits scheduled based on enrollment rate, data volume, and risk profile (every 6–8 weeks or as defined in Monitoring Plan).

6. Escalation
Immediate escalation required for critical GCP violations or safety concerns.
Document escalations in Escalation Log (Annexure-4).

7. Archiving
Archive all monitoring visit reports, SDV checklists, CAPA documentation, and escalation logs in TMF.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• SDV: Source Data Verification
• IP: Investigational Product
• CAPA: Corrective and Preventive Action

Documents

1. Monitoring Visit Checklist (Annexure-1)
2. Monitoring Visit Report (Annexure-2)
3. CAPA Log (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Monitoring Clinical Trials
• CDSCO – Monitoring Requirements
• WHO – Onsite Monitoring Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Visit Checklist

Annexure-2: Monitoring Visit Report

Annexure-3: CAPA Log

Annexure-4: Escalation Log

Revision History

For more SOPs visit: Pharma SOP